• DKSH agreed to buy rights to Bayer’s Meliane oral contraceptive brand across 30 markets spanning Europe, North Africa, Asia, and the Middle East.
• Meliane generated about CHF 15 million in net sales in 2025.
• Deal targets expansion of DKSH’s Healthcare own-brands portfolio, with women’s health as a priority segment.
• Most markets overlap with DKSH’s existing European commercial platform, supporting distribution synergies.
• Closing is expected in the third quarter of 2026, subject to customary conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DKSH Holding AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2371470_en) on July 27, 2026, and is solely responsible for the information contained therein.